Lv7
5005 积分 2022-01-12 加入
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer
27天前
已完结
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study
1个月前
已完结
Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial
1个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
3个月前
已完结
Prevalence, therapeutic approaches, and survival rates of brain metastases in non-small cell lung cancer: a multi-institutional claims-based study from 2014 to 2024
6个月前
已完结
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
6个月前
已完结
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
6个月前
已完结
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
6个月前
已完结
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
6个月前
已完结
皖公网安备34019202002308
